No Detail Found!

Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and (NF-kB) Levels in Type 2 Diabetes.

Author(s)
Xia Liu Department of Endocrinology, The Second Hospital Affiliated to Lanzhou University, 730030, China
Jinwen Huang Department of Anesthesiology, Gansu People's Hospital, 730000, China
Jiawei Li College of Basic Medicine, Gansu University of Traditional Chinese Medicine, 730000, China
Qinghua Mao Clinical Laboratory, The First People's Hospital of Jining, 272002, China
Jirui He Department of Endocrinology, The Second Hospital Affiliated to Lanzhou University, 730030, China
Abstract
Objective: To investigate the effects of liraglutide combined with insulin on oxidative stress and expression levels of serum monocyte chemoattractant protein-1 (MCP-1) and nuclear factor-kB (NF-kB) in patients with type 2 diabetes. Study Design: An experimental study. Place and Duration of Study: Department of Endocrinology, the Second Hospital Affiliated to Lanzhou University, China, from September 2016 to January 2018. Methodology: Ninety-two patients with type 2 diabetes were selected as objects of study. They were randomly divided into observation group and control group, with 46 cases in each group. The control group was treated with insulin alone, and the observation group was treated with liraglutide in combination with insulin. The changes of levels of blood glucose, serum MDA, SOD, MCP-1 and NF-kB were compared between the two groups before and after treatment, and the blood glucose target rate after treatment was compared between the two groups. Results: Before treatment, there were no significant differences in fasting blood glucose, 2h postprandial blood glucose, serum MDA, serum SOD, serum MCP-1 and serum NF-kB between the two groups (p=0.885, 0.961, 0.919, 0.990, 0.954 and 0.837, respectively). After treatment, levels of the fasting blood glucose, 2h postprandial blood glucose, serum MDA, serum MCP-1, and serum NF-kB in the observation group were lower than those in the control group (all p<0.001). The serum SOD level and blood glucose target rate were higher in the observation group than those in the control group (p<0.001 and p=0.010, respectively). Conclusion: Liraglutide combined with insulin therapy can effectively improve blood glucose levels in type 2 diabetic, reduce oxidative stress status, decrease the expression of serum MCP-1 and NF-kB, and inhibit the internal inflammatory response.
Publication Details
Page(s) 218-221
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 3, Year: 2019

Request the full text from PASTIC

References
BellamyL,CasasJP,HingoraniAD,WilliamsD., 2009.Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis,Lancet 373 1773 -9
RobertsonRP,HarmonJS, 2007.Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase,Febs Lett 581 3743 -8
AljadaA,GhanimH,SaadehR, 2001.Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells,J Clin Endocrinol Metab 86 450 -3
ParkesDG,MaceKF,TrautmannME, 2013.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone,GLP-1. Expert Opin Drug Discov 8 219 -44
AhrénB., 2011.GLP-1 for type 2 diabetes,Exp Cell Res 317 1239 -45
DharmalingamM,SriramU,BaruahMP, 2011.Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus,Indian J Endocrinol Metab 15 9 -17
BregenholtS,MøldrupA,BlumeN,KarlsenAE,Nissen FriedrichsenB,TornhaveD, 2005.The long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro,Biochem Biophys Res Commun 330 577 -84
RolinB,LarsenMO,GotfredsenCF,DeaconCF,CarrRD,WilkenM, 2002.The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice,Am J Physiol Endocrinol Metab 283 E745 -52
MeraniS,TruongW,EmamaulleeJA,TosoC,KnudsenLB,ShapiroAM, 2008.Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice,Endocrinology 149 4322 -8
1984.Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial,N Engl J Med 311 365 -72
CroomKF,MccormackPL, 2009.Liraglutide: a review of its use in type 2 diabetes mellitus,Drugs 69 1985 -2004
ShimodaM,KandaY,HamamotoS,TawaramotoK,HashiramotoM,MatsukiM, 2011.The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes,Diabetologia 54 1098 -108
AppelLJ,SacksFM,CareyVJ,ObarzanekE,SwainJF,MillerER, 2005.Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial,JAMA 294 2455 -64
HanefeldM,AppeltD,EngelmannK,SandnerD,BornsteinSR,GanzX, 2016.Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy,Horm Metab Res 48 529 -34
TykhomyrovAA,ShramSI,GrinenkoTV, 2015.Role of angiostatins in diabetic complications,Biomed Khim 61 41 -56
LindblomR,HigginsG,CoughlanM, 2015.Targeting mitochondria and reactive oxygen species-driven pathogenesis in diabetic nephropathy,Rev Diabet Stud 12 134 -56
CaoHX,HeLQ,ShenYJ, 2004.Changes of SOD, GSH and MDA in renal tissues of diabetic hyperlipidemia rats,Zhong Xi Yi Jie He Xue Bao 2 36 -8
PadalkarRK,ShindeAV,PatilSM, 2012.Lipid profile, serum malondialdehyde, superoxide dismutase in chronic kidney diseases and type 2 diabetes mellitus,Biomed Res 23 207 -10
HaradaC,OkumuraA,NamekataK,NakamuraK,MitamuraY,OhguroH, 2006.Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy,Diabetes Res Clin Pract 74 249 -56
SunX,HanF,YiJ,HanL,WangB, 2011.Effect of aspirin on the expression of hepatocyte NF-B and serum TNF- in streptozotocin-induced type 2 diabetic rats,J Korean Med Sci 26 765 -70
0

Citations

0

Downloads

153

Views